Biomedical subjects

A Biłan

Publications and source records attributed to A Biłan.

12 recordsLinked to original sources

PubMed2001

[Methylenetetrahydrofolate reductase gene polymorphism in patients with type 2 diabetes].

Hyperhomocysteinemia is recognised as a risk factor of ischaemic heart disease and vascular complications of arterial hypertension. Methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism is associated with hyperhomocysteinaemia. The aim of the study was the assessment of an association of the above polymorphism with type 2 diabetes with special attention to myocardial infarction and arterial hypertension accompanying diabetes. The study group consisted of 172 type 2 diabetics. 172 control subjects with normal glucose tolerance were age and sex matched to patients with diabetes. C677T polymorphism in MTHFR gene locus was detected using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. CT and TT genotypes were found more often among diabetics (OR 1.83, 95% CI 1.16-2.89; p < 0.01). This finding may be secondary to the excess of T allele bearers among diabetics with myocardial infarction when compared to diabetics without infarction and to control group. Upon obtained results the potential role of genotypes CT and TT as risk factors of myocardial infarction among patients with type 2 diabetes could not be excluded (OR 2.33, 95% CI 0.93-5.8; p = 0.07). Genotypes containing T allele are not associated with diabetes type 2 and concomitant arterial hypertension (OR 1.45, 95% CI 0.89-2.57; p = 0.14). A confirmation in further studies is needed for the presented findings.

Aged↗

PubMed2001

Cardiopulmonary manifestations of subarachnoid hemorrhage--a case report.

The study presents a case of a 48-year-old female patient, in whom first symptoms of subarachnoid hemorrhage were suggestive of acute pulmonary oedema, caused by acute left ventricular insufficiency, evoked by myocardial infarction. The authors discuss the course of illness, diagnostic difficulties and changes in circulatory system, which can appear as a result of subarachnoid hemorrhage.

Cardiovascular Diseases↗

PubMed2000

[Effect of dihydrotestosterone treatment on exercise induced ischemia in men with stable ischemic heart disease].

Many studies report the negative correlation between the endogenous testosterone (T) level and majority of risk factors for arteriosclerosis, as well as the presence and the extent of coronary artery disease (CAD) in men. Dihydrotestosterone (DHT) as a non-aromatizable androgen produces more favourable changes in the hormone profile than T. A constant level of androgens, independent on liver function, may be achieved by their transdermal administration. The aim of our study was to determine in a double-blind placebo study whether a 12-week treatment with transdermal DHT can decrease exercise-induced ischaemia in males with CAD. All patients underwent symptom-limited treadmill stress testing at the beginning of the study and after DHT treatment. The selected preliminary results are presented in this paper. Until now the study group has comprised ten men with stable CAD and decreased morning total T concentration. No side effects of treatment were noted during the study. Chronic DHT administration increased significantly: total exercise time, time to the onset of angina and time to 1 mm ST depression. Our results are consistent with the previous publications investigating T effects. The changes of heart rate and systolic blood pressure indicate rather direct coronary-relaxing effect of DHT than peripheral one.

Administration, Cutaneous↗

PubMed1999

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): echocardiographic substudy--three months follow-up.

The ESS-1 study was designed to evaluate the long-term effects of the angiotensin converting enzyme inhibitor (ACEI) enalapril (10 mg per day) on the cardio-pulmonary system in patients with scleroderma (SSc). We estimated changes in heart diameters, systolic and diastolic left ventricle function and mean values of pulmonary artery pressure after 3 months treatment. The study group comprise 41 patients with SSc. 18 patients received placebo and 23 ones were given enalapril. After 3 months of treatment we did not observe statistically significant differences in heart diameters and left ventricle systolic function parameters between treated group and placebo. Enalapril therapy did not affect left ventricle diastolic function, nevertheless differences in MVA were almost of statistical significance. Echocardiographic signs of pulmonary hypertension were found in 4 patients.

Adult↗

PubMed1999

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): ECG exercise testing--three months follow-up.

The ESS-1 study was designed to evaluate the long-term effects of the angiotensin-converting enzyme inhibitor (ACEI) enalapril (10 mg per day) on cardiopulmonary system of patients with systemic sclerosis (SSc). Exercise testing is used not only for estimation of coronary reserve but also physical capacity--the major determinant of quality of life. In each patient included to the ESS-1 study we performed ECG exercise test on treadmill (5 times at intervals of 3 months). The first follow-up was completed by 41 patients (23 patients in enalapril group and 18 in placebo group). The exercise duration in the placebo group was 683 +/- 295 sec and in enalapril group 768 +/- 173 sec. After 3 months of study there were no significant differences in both groups (758 +/- 271 sec and 720 +/- 191 sec respectively). The analysis of ST segment deviation did not provide any significant changes after 3 months of treatment. We conclude that 3 months enalapril treatment did not improve exercise tolerance in patients with systemic sclerosis.

Adult↗

PubMed1999

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): pulmonary substudy--effects of three month treatment.

The ESS-1 study is designed to evaluate the long-term effects of enalapril on cardiopulmonary system of patients with systemic sclerosis (SSc). During the one year study period 5 visits are scheduled at 3 months intervals. The effect of 3 months treatment with enalapril (10 mg per day) on lung function was studied in 18 patients with SSc (enalapril group) and compared with controls--23 patients with Ssc (placebo group), mean age, SSc duration, gender and % of patients with dcSSc did not differ significantly in both groups. We performed body plethysmography for total airways resistance (Rtot), and static lung volumes (TLC, ITGV and RV), spirometry for FEV1 and FVC and we measured flow parameters (PEF, FEF). We compared initial lung function (first examination) with results after 3 months treatment (second examination) in the enalapril and in the placebo group. Mean values of Rtot, ITGV and RV did not differ significantly in the enalapril group or in the placebo group before and after treatment but FVC, FEV1 and FEF50 were significantly lower in the enalapril group and did not change in the placebo group after three months. We conclude that 3 month treatment with enalapril worsens spirometry of SSc patients. We did not observe any changes in lung functions in the control group in the same three month period.

Adult↗

PubMed1999

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): electrocardiographic substudy--three months follow-up.

UNLABELLED: The ESS-1 study was designed to evaluate the long-term effects of enalapril (10 mg per day) on the cardiopulmonary system of patients with systemic sclerosis (SSc). The 3 months follow-up was completed by 41 patients (23 patients in enalapril group and 18 in placebo group). We analysed conventional time domain signal averaged ECG (SAECG). Late potentials were considered to be present in QRS duration (QRS) was > 114 ms or root mean square of last 40 ms (RMS40) was < 20 microV or terminal signal duration under 40 microV (LAS40) was > 38 ms at 40 Hz. At the beginning of study the prevalence of abnormal SAEG parameters was similar in both groups. We observed one abnormal parameter among 13% of patients in enalapril group and 16.7% of patients in placebo group. There were 2 abnormal parameters in 26.1% of patients in enalapril group and 16.7% of patients in placebo group. After three months of treatment we did not find any patient with 2 parameters of late potentials in enalapril group and only 8.7% of patients with one such parameter. In placebo group no substantial improvement was observed. CONCLUSION: The 3 months enalapril treatment seems to decrease the incidence of late potentials in patients with systemic sclerosis.

Adult↗

PubMed1999

[Dihydrotestosterone therapy of men with coronary artery disease and processes of peroxidation].

In 11 men after myocardial infarction (mean age 58.8 years) influence of 3 months transdermal dihydrotestosterone (DHT) treatment on malondialdehyde (MDA), total cholesterol, HDL cholesterol, triglycerides and platelets was estimated. Decrease in MDA concentration after DHT treatment only in men with low (< 13 nmol/l) testosterone (T) level (p = 0.06) was observed. MDA concentration after 3 months DHT treatment was significantly lower in hypotestosteronemic in comparison to normotestosteronemic men (p < 0.05). Plasma lipid levels and platelet count were not affected by DHT administration. Decrease serum MDA concentration in low testosterone men with coronary artery disease may suggest that DHT treatment in this group has beneficial effects on peroxidation processes.

Aged↗

PubMed1999

[Bronchial hyperreactivity as a factors of chronic obstructive pulmonary disease development in the population of the Bogdanka coal miners].

The aim of the study was to assess the role of bronchial hyperreactivity in the development of chronic airflow obstruction in the population of the Bogdanka (Lublin Basin) coal miners. The population examined consisted of 1456 coal miners working underground in the Bogdanka colliery. The methods of the study included plethysmographic measurements of total airway resistance (Raw), spirometric measurements of forced expiratory volume in one second (FEV1), and determination of forced expiratory flowa at 75, 50 and 25 per cent of vital capacity (FEF75, FEF50 and FEF25%VC). The measurements were repeated twice--before and after administration of 0.2% solution of methacholine (1 min inhalation). Pulmonary function tests were also performed 8 years after initial measurements. The increase in the Raw value above 0.6 kPa/l/s was observed in 5.5% of the population examined. In this group of subjects the skin prick tests with common allergens, measurements of total immunoglobulin E (IgE) levels and determination of blood eosinophils count were performed. Only 12% of all hyperreactives (Raw increase > 0.6 kPa/l/s) showed features of atopy--positive skin prick tests, raised IgE levels, and increase in blood eosinophils count. Using a survival analysis as a statistical tool we evaluated for how long the pulmonary function tests remained within normal ranges in two groups: hyperreactives and controls. All hyperreactives (atopic and non-atopic) showed significantly higher risk of lung function decrease below the normal values as compared with the control group.

Adult↗

PubMed1999

[Angiotensin converting enzyme gene polymorphism in type 2 diabetes mellitus].

The aim of this study is the assessment of the association of human angiotensin-converting enzyme gene I/D polymorphism with type 2 diabetes in 155 diabetic patients and 139 healthy individuals. These polymorphism were studied using polymerase chain reaction. Angiotensin converting enzyme gene DD genotype associated with type 2 diabetes in overweight and obese patients and patients with normal total plasma cholesterol. There is also association of DD genotype with arterial hypertension and with myocardial infarction in type 2 diabetic patients.

Aged↗

PubMed1998

Right ventricular function in systemic hypertension.

The aim of the study was the assessment of right ventricular (RV) structure and diastolic function in hypertensive subjects. The study group consisted of 44 patients with untreated, mild to moderate essential systemic hypertension. All the patients were in sinus rhythm, no symptoms of congestive heart failure, ischaemic or valvular heart disease and lung disorders were found. Twenty-six healthy subjects were the control group. M-mode echocardiographic measurements of the right ventricular wall (RVW) diastolic thickness, right ventricular outflow tract diameter (RVOTD), left ventricular (LV) structure and LV systolic function were performed. Pulsed Doppler echocardiography was used to measure peak early (TE) and peak atrial (TA) right ventricular diastolic filling velocities as well as velocity-time integrals (VTI-TE and VTI-TA). TE:TA and VTI-TE:VTI-TA ratios were calculated. Similar parameters of the left ventricular diastolic filling were recorded at the level of mitral annulus. Mean pulmonary artery pressure (MPAP) was measured non-invasively by the estimation of pulmonary artery systolic flows. We demonstrated in hypertensive patients significantly thicker RVW (3.94 vs 2.8 mm, P < 0.001) and increased LV mass. In the hypertensive, increased TA and VTI-TA and diminished TE:TA and VTI-TE:VTI-TA ratios were recorded, indicating the abnormalities of RV diastolic function. RV diastolic filling parameters correlated positively with corresponding parameters of LV filling. The results of our study demonstrate that impairment of LV diastolic function, the common finding in systemic hypertension, is associated with diastolic disturbances of the right ventricle. RVW thickening and hypertrophy of interventricular septum seem to be major factors influencing RV diastolic function.

Adult↗

PubMed1996

[Echocardiographic evaluation of pulmonary artery flow parameters in patients with chronic pulmonary disease].

This study aimed at comparing the Doppler echocardiographic artery blood flow parameters in patients with and without chronic obstructive pulmonary disease (COPD), and estimating an effect of the present degree of airway obstruction on systolic functioning of the right ventricle. The study included 28 patients with COPD, and 22 patients without COPD constituting a control group. Pulmonary functional tests have been performed with the use of body plethysmography. Doppler echocardiographic assessment of the pulmonary artery flow included a measurements the acceleration time (AcT), and right ventricular ejection time (RVET). Both AcT and RVET have been corrected for the heart rate. Corrected AcT shorter than 100 ms has been considered specific for the pulmonary hypertension (PH). AcT in the studied group of patients ranged from 67 ms to 143 ms (mean 106 +/- 21), and has been significantly shorter than that in the control group. However, no correlation between body plethysmographic findings and echocardiographic measurements has been found in COPD patients. Echocardiography is a sensitive technique detecting PH. As spirometric findings do not predict development of the cor pulmonale, Doppler echocardiographic evaluation of the blood flow in pulmonary artery may serve as a screening test.

Adult↗